Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 13,110 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06158919Recruiting
Immunotherapy Plus Targeted Therapy and Chemo for Stomach Cancer
This trial tests a combination of immunotherapy (PD-1 inhibitor), a targeted drug (fruquintinib), and chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that is HER2-negative. It aims to see if this combination can shrink tumors and help people live longer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06160206RecruitingPhase 2
Study of retifanlimab, bevacizumab, and radiation for recurrent glioblastoma
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
Scottsdale, ArizonaAges 18 years+ - NCT06160596Recruiting
Understanding long-term cancer survival in hard-to-treat tumors
This study looks at why some people with hard-to-treat cancers live much longer than expected. It collects tumor samples to search for clues that might help future patients.
VillejuifAges 18 years+ - NCT06160843RecruitingPhase 2
Pembrolizumab and olaparib for relapsed peripheral T-cell lymphoma
This trial tests whether combining two targeted drugs, pembrolizumab and olaparib, can help people with peripheral T-cell lymphoma that has come back or not responded to previous treatment. The goal is to find a new option for this type of cancer.
SingaporeAges 21–99 - NCT06161545RecruitingPhase 2
Immunotherapy before surgery for head and neck cancer
This trial tests whether giving a combination of immunotherapy drugs (pembrolizumab, N-803, and possibly PD-L1 t-haNK cells) before surgery can help treat head and neck cancer that has not been treated yet. It is for people whose cancer is p16-negative (a specific marker) and is at an intermediate or high risk of coming back.
Bethesda, MarylandAges 18–120 - NCT06161818RecruitingPhase 2
Combined therapy before surgery for lymph node-positive esophageal cancer
This trial is testing a combination of chemotherapy and radiation (called total neoadjuvant therapy) before surgery for a type of esophageal cancer that has spread to lymph nodes. The goal is to see if this approach improves outcomes.
Eindhoven, North BrabantAges 18 years+ - NCT06162377RecruitingPhase 4
Methylnaltrexone before surgery for mouth cancer
This trial tests if taking methylnaltrexone for two weeks before surgery can help people with mouth cancer. It is a small, early study to see how the drug affects the tumor and the body.
Houston, TexasAges 18 years+ - NCT06163391RecruitingPhase 1
SOT201 for advanced solid tumors
This trial tests a new drug called SOT201 for people with advanced solid cancers that have stopped responding to other treatments. It helps the immune system fight the cancer more effectively.
Houston, TexasAges 18 years+ - NCT06163924Recruiting
Heart risk reduction in prostate cancer patients on hormone therapy
This study tests whether a team of doctors, nurses, and other specialists can help reduce the risk of heart problems in men with prostate cancer who are on hormone therapy (ADT). It focuses on providing extra support for heart health.
Hong KongAges 18–80 - NCT06165900RecruitingPhase 2
Radiation plus immunotherapy and chemo before surgery for triple-negative breast cancer
This trial tests combining stereotactic radiation therapy with immunotherapy (adebrelimab) and chemotherapy (nab-paclitaxel and carboplatin) before surgery for early or locally advanced triple-negative breast cancer. The goal is to see if this combination improves treatment response.
Shenyang, LiaoningAges 18–75 - NCT06166953Recruiting
Smartphone education for breast reconstruction recovery
This study tests if a smartphone-based education program helps women who are recovering from breast reconstruction surgery after a mastectomy. If you are a Turkish speaker with a compatible smartphone, you may be able to join.
Ankara, ÇankayaAges 18–75 - NCT06168786RecruitingPhase 2
New drug combo and radiation for advanced colorectal cancer
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
Wuhan, HubeiAges 18–75 - NCT06169163Recruiting
Breath test for esophageal squamous cell cancer
This study looks at chemicals in your breath to see if they can help detect a type of esophageal cancer (squamous cell carcinoma) early. You may join if you have untreated squamous cell esophageal cancer, or if you are having a routine endoscopy for stomach issues and your results are normal or show a benign condition.
London, Greater LondonAges 18–90 - NCT06170710RecruitingPhase 2
Immunotherapy after chemoradiation for high-risk head and neck cancer
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
Beijing, Beijing MunicipalityAges 18–70 - NCT06171269Recruiting
MRI-guided radiation dose reduction for prostate cancer
This trial tests whether using MRI scans to guide radiation can allow lower doses to the healthy parts of the prostate, potentially reducing side effects. It is for men with intermediate- or high-risk prostate cancer that can be seen on MRI and has not spread.
Chicago, IllinoisAges 18 years+ - NCT06171750RecruitingPhase 1
Study of ANK-101 for advanced solid tumors
This trial tests a new drug, ANK-101, injected directly into tumors to help fight advanced solid tumors that have spread or can't be treated with standard therapies. It may be an option if you have a tumor that can be reached for injection.
Bethesda, MarylandAges 18 years+ - NCT06177041RecruitingPhase 3
M108 plus chemo for CLDN18.2-positive stomach cancer
This trial tests a new drug (M108) combined with standard chemotherapy (CAPOX) as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has a specific protein called Claudin 18.2. The goal is to see if adding M108 helps improve outcomes compared to chemotherapy alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06176989RecruitingPhase 2
Enasidenib for IDH2-mutated sinonasal and skull base tumors
This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.
Bethesda, MarylandAges 18–120 - NCT06177015RecruitingPhase 3
Darolutamide with chemo for metastatic prostate cancer
This trial tests a new way of using darolutamide (a hormone therapy) together with standard chemotherapy (docetaxel) and hormone therapy (ADT) for men with prostate cancer that has spread. The goal is to see if taking darolutamide on an intermittent schedule works as well as continuous treatment.
Nanjing, JiangsuAges 40–80 - NCT06177093Recruiting
Higher dose prostate radiation with MRI guidance
This study tests a higher dose of radiation for prostate cancer using an MRI-guided machine (MR-Linac). It aims to see if a more targeted dose can be safely given to the tumor while protecting healthy tissue.
Toronto, OntarioAges 18 years+ - NCT06180642Recruiting
Ultrasound for arm tissue after breast cancer
This study uses ultrasound to examine arm tissue in women who have had breast cancer. It aims to see if ultrasound can reliably detect changes in arm soft tissue, which may help identify or prevent arm swelling and stiffness after treatment.
AntwerpAges 18 years+ - NCT06182657Recruiting
Nasopharyngeal cancer response to induction chemotherapy
This study looks at how well nasopharyngeal cancer (NPC) responds to the first round of chemotherapy before other treatments. It aims to see if the amount of tumor shrinkage can help predict outcomes and guide future care for people with advanced NPC.
Nanchang, JiangxiAges 18 years+ - NCT06182774RecruitingPhase 3
Fixed vs ongoing treatment for older adults with new myeloma
This trial compares stopping treatment after a set number of cycles versus continuing it for people over 65 or those who cannot have a stem cell transplant. It tests whether a fixed treatment period works as well as long-term treatment for newly diagnosed multiple myeloma.
Edmonton, AlbertaAges 18 years+ - NCT06185062Recruiting
Pelvic cancer registry for online adapted radiotherapy
This study collects data from patients receiving a type of radiation therapy that is adjusted in real-time. It aims to learn more about how well this approach works for pelvic and chest tumors.
GöttingenAges 18 years+
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 13,110 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.